Filspari Tablet, Film Coated
Product Images NDC 68974-200

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Filspari (NDC 68974-200). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Travere Therapeutics, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Effective Birth Control Options (Birth Control Options)

A table titled 'Effective Birth Control Options' listing four contraception options. Options 1, 2, and 3 include choices of methods such as intrauterine devices, hormonal contraceptives, diaphragm or cervical cap with spermicide, often combined with male condoms. Option 4 lists partner's vasectomy plus additional contraceptive methods. The table organizes birth control methods by combinations for effectiveness.*

FDA Label Image

Figure 1 (Figure 1)

A line graph comparing the adjusted geometric mean percent change over 36 weeks between FILSPARI (sparsentan) and irbesartan. FILSPARI shows a steeper decline in percent change compared to irbesartan, with data points and confidence intervals plotted at multiple visit weeks (baseline, 4, 6, 12, 24, and 36). Sample sizes for each week and drug are indicated below the x-axis.*

FDA Label Image

Sparsentan Structure (Sparsentan Structure)

Chemical structure diagram of sparsentan, the active ingredient in FILSPARI. The structure shows multiple aromatic rings, a sulfonamide group, and heterocyclic components characteristic of the molecule.*

FDA Label Image

Principal Display Panel (200 mg Tablet Label)

FILSPARI (sparsentan) film-coated tablets 200 mg oral dosage form. The label shows the product name, active ingredient, strength, and quantity of 30 tablets. It includes directions for storage and a note to dispense the accompanying medication guide. Manufactured for Travere Therapeutics, Inc., and by Catalent in Kansas City, MO. The label contains a barcode, QR code, expiration date placeholder, and lot number placeholder.*

FDA Label Image

Principal Display Panel (400 mg Tablet Label)

FILSPARI 400 mg (sparsentan) film-coated tablets packaging label showing 30 tablets per container. The label includes dosage strength, NDC 68974-400-30, Rx only, manufacturer Travere Therapeutics, Inc., and manufacturer Catalent with their locations, and storage instructions. A QR code and barcode are also visible on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.